Bladder Cancer Coverage from Every Angle

Arlene O. Siefker-Radtke, MD, on Comparing Immunotherapy and Antibody-Drug Conjugates for Urothelial Bladder Cancer

Posted: Friday, March 19, 2021

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, talks about how different classes of agents might be used to extend survival, whether sequentially or in combination. She also touches on preventing or mitigating toxicities related to immune checkpoint inhibitors.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.